ClinicalTrials.gg
CompletedNCT02648724Updated Jun 22, 2022Results posted

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

A Phase 1/2 interventional study of Sym015 in Oncology, MET Gene Amplification and NSCLC, sponsored by Symphogen A/S. Completed at 27 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-22.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Symphogen A/S · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
1,485th of 3,001
57 · median 56
Started
2016
with 136 others
Phase 1/2
487 of 3,374
118 open now
Registered
1,676th of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,485th largest by enrollment of the 3,001 interventional ones that give a count, is one of 137 that started in 2016, is one of 487 in phase 1/2, and was the 1,676th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.

Read the detailed description

In the first part of the study (Part 1, dose-escalation), Sym015 was evaluated for safety and tolerability. Additionally, the recommended Phase 2 dose (RP2D) was to be determined. Sym015 was given at different dose levels on an every second week (Q2W) dosing schedule. Each patient was given one single weight based dose level.

In the second part of the study (Part 2, dose-expansion), dosing was to be at the RP2D on a Q2W dosing schedule. Three cohorts were included:

  • Basket Cohort: Patients with KRAS wild-type (WT) advanced solid tumor malignancies with MET-amplification and without therapeutic options. Patients must have no prior therapy with MET-targeting agents, except a subset of patients having received prior therapy with a MET-targeting tyrosine kinase inhibitor (TKI). As of December 2018, accrual to this cohort was suspended.
  • Non-Small Cell Lung Carcinoma (NSCLC) MET-Amplified Cohort: Patients with advanced NSCLC with MET-amplification, and without available therapeutic options. Patients may have received prior therapy with MET-targeting and/or epidermal growth factor receptor (EGFR)-targeting agents.
  • NSCLC with MET exon 14 skipping alteration (METex14del) Cohort: Patients with advanced NSCLC METex14del, and without therapeutic options. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.
03

Conditions studied

  • Oncology
  • MET Gene Amplification
  • NSCLC
  • MET Gene Mutation
  • Non Small Cell Lung Cancer

Browse trials for

Keywords

  • Advanced Solid Tumor Malignancies
  • MET Gene Amplification
  • MET Amplification
  • Wild-type
  • NSCLC
  • METex14del
  • Non-Small Cell Lung Carcinoma
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 57 is close to the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Symphogen A/S is the lead sponsor of 16 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status (PS) of 0 or 1.
  • >3 months assessed during Screening.
  • Documented (- or cytologically-proven) solid tumor that is locally advanced or , and that is to standard therapy or for which no standard therapy is available or accessible.
  • If female and of : a negative pregnancy test.
  • Male or female: either not of childbearing potential or agreeing to use a medically effective method of as per institutional standards during the trial and for 4 months after the last dose of trial drug.
  • Part 1 ONLY: Tumor documented to be KRAS WT by local assessment.
  • Part 2 ONLY:

    • according to v1.1 that has been confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks prior to Cycle 1/Day 1 (C1/D1).
    • Basket Cohort ONLY:

      • Tumor documented to be KRAS WT by local assessment according to institutional standards. If KRAS WT is not previously documented and if is not available for pretrial assessment, patient must be willing to undergo a tumor biopsy to confirm eligibility.
      • Confirmed MET-amplification by local assessment.
      • No prior therapy with MET-targeting agents (except a subset of patients having received prior therapy with a MET-targeting TKI).
      • Willingness to undergo a pre- and post-dosing biopsy (maximum of 2 biopsies) from primary or metastatic tumor site(s) considered safely accessible for biopsy
    • NSCLC MET-Amplified Cohort ONLY:

      • Documented NSCLC meeting disease criteria as defined per protocol.
      • Documented MET-amplification.
      • May have received prior therapy with MET-targeting and/or EGFR-targeting agents (antibodies or TKIs).
      • Willingness to undergo a pre-dosing biopsy (mandatory unless a recent tumor biopsy is available), and potentially a biopsy at the End of Cycle 2 (EOC2) (optional), from a primary or metastatic tumor site considered safely accessible for biopsy.
    • NSCLC METex14del Cohort ONLY:

      • Documented NSCLC meeting disease criteria as defined per protocol.
      • Documented METex14del (tumors need not be MET-amplified).
      • May have received prior therapy with MET-targeting and/or EGFR-targeting agents (antibodies or TKIs).
      • Willingness to undergo a pre-dosing biopsy (mandatory unless a recent tumor biopsy is available), and potentially a biopsy at the EOC2 (optional), from a primary or metastatic tumor site considered safely accessible for biopsy.

Exclusion criteria

Exclusion Criteria:

  • Any antineoplastic agent for the primary (standard or ) without delayed toxicity within 4 weeks or 5 plasma half-lives, whichever is shortest, prior to C1/D1, except nitrosoureas and mitomycin C within 6 weeks prior to C1/D1.
  • or systemic hormonal therapy within 2 weeks prior to C1/D1, with exceptions.
  • Use of hematopoietic growth factors within 2 weeks prior to C1/D1.
  • Active second malignancy or history of another malignancy within the last 3 years, with exceptions.
  • Central nervous system (CNS) malignancy including primary malignancies of the CNS and known, untreated CNS or , or spinal cord compression; patients with any of these not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required.
  • Inadequate recovery from an acute toxicity associated with any prior antineoplastic therapy.
  • Major surgical procedure within 4 weeks prior to C1/D1 or inadequate recovery from any prior surgical procedure.
  • Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 1 month prior to C1/D1, unless adequately treated and stable.
  • Active uncontrolled bleeding or a known bleeding diathesis.
  • Significant cardiovascular disease or condition.
  • Abnormal hematologic, renal or hepatic function.
  • Part 2 ONLY:

    • Radiotherapy against target lesions within 4 weeks prior to C1/D1, unless there is documented progression of the lesion following the radiotherapy.
    • Basket Cohort ONLY:

      • Prior therapy with MET-inhibiting agents (exceptions will be a subset of patients that will be entered to the Basket Cohort after having received prior therapy with a MET-targeting TKI).
      • Prior therapy with antibody to hepatocyte growth factor (HGF).
    • Basket Cohort and NSCLC MET-Amplified Cohort ONLY:

      • Tumor status demonstrating MET-polysomy in the absence of MET-amplification, as specified per protocol. Patients in the NSCLC METex14del Cohort with polysomy are eligible.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Part 1: 6 mg/kg

    Sym015 was tested in four dose titration cohorts. Patients in this cohort received 6 mg/kg. A substitute or an additional dose level could potentially be evaluated.

    Drug: Sym015

  • Experimental
    Part 1: 12 mg/kg

    Sym015 was tested in four dose titration cohorts. Patients in this cohort received 12 mg/kg. A substitute or an additional dose level could potentially be evaluated.

    Drug: Sym015

  • Experimental
    Part 1: 18 mg/kg

    Sym015 was tested in four dose titration cohorts. Patients in this cohort received 18 mg/kg. A substitute or an additional dose level could potentially be evaluated.

    Drug: Sym015

  • Experimental
    Part 1: 24 mg/kg

    Sym015 was tested in four dose titration cohorts. Patients in this cohort received 24 mg/kg. A substitute or an additional dose level could potentially be evaluated.

    Drug: Sym015

  • Experimental
    Part 2: Basket Cohort

    Patients with KRAS WT advanced solid tumor malignancies with MET-amplification were to receive Sym015 at the RP2D. Included in this group was a subset of patients who have received prior therapy with a MET-targeting TKI.

    Drug: Sym015

  • Experimental
    Part 2: NSCLC MET-Amplified Cohort

    Patients with advanced NSCLC with MET-amplification were to receive Sym015 at the RP2D. Patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.

    Drug: Sym015

  • Experimental
    Part 2: NSCLC METex14del Cohort

    Patients with advanced NSCLC with METex14del were to receive Sym015 at the RP2D. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents. mutation.

    Drug: Sym015

Interventions

  • DrugSym015

    Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.

    Also known as: Anti-MET

07

What researchers measure

Primary outcomes

  1. Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration

    The primary objective of Part 1 was to assess the safety and tolerability of Sym015 on a Q2W schedule. This was assessed by evaluating the occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of Sym015 administration. Q2W = every second week.

    Time frame: Cycle 1, the initial 28-day period of Q2W dosing

  2. Part 2: Documented, Confirmed Objective Response (OR)

    The primary objective of Part 2 was to evaluate the antitumor activity of Sym015 when administered at the Q2W RP2D to patients in the different cohorts. Documented OR was defined as partial response \[PR\] or complete response \[CR\]) as assessed by CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; CR = Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). Q2W = every second week. RP2D = recommended phase 2 dose.

    Time frame: 24 months

Secondary outcomes

  1. Part 1: Determine a Q2W RP2D of Sym015.

    Determination based on an evaluation of the patient data for DLTs from Part 1. Q2W = every second week. RP2D = recommended phase 2 dose.

    Time frame: 12 Months

  2. Immunogenicity of Sym015: Part 1.

    Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.

    Time frame: Cycle 1: Day (D) 1, Cycle 3, 5, 7: D1 (+-2), End of treatment: At or by D10, Follow-up: 1 month after last dose of study treatment (30+7D)

  3. Immunogenicity of Sym015: Part 2.

    Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.

    Time frame: Cycle 1: Day (D) 1, Cycle 2, 3, 5, 7: D1 (+-2), End of treatment: At or by D10, Follow-up: 1 month after last dose of study treatment (30+7D)

  4. Part 1: Area Under the Concentration-time Curve in a Dosing Interval (AUC) Following 1st Dose

    Estimated using non-compartmental methods and actual time points following the first dose of Sym015.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  5. Part 2: Area Under the Concentration-time Curve in a Dosing Interval (AUC)

    Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  6. Part 1: Cmax

    Maximum serum concentration was derived from observed data.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  7. Part 2: Cmax

    Maximum serum concentration was derived from observed data following the first dose of Sym015 for the full basket cohort.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  8. Part 1: Time to Reach Maximum Concentration (Tmax)

    Time to reach maximum concentration (Tmax) was derived from observed data.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  9. Part 2: Time to Reach Maximum Concentration (Tmax)

    Time to reach maximum concentration (Tmax) was derived from observed data following the first dose of Sym015 for the full basket cohort.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  10. Part 1: Trough Concentration (Ctrough)

    Ctrough was derived from observed data.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  11. Part 2: Trough Concentration (Ctrough)

    Ctrough was derived from observed data following the first dose of Sym015 for the whole basket cohort.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  12. Part 1: Elimination Half-life (T½)

    Estimated using non-compartmental methods and actual time points.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  13. Part 2: Elimination Half-life (T½)

    Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  14. Part 1: Clearance (CL)

    Estimated using non-compartmental methods and actual time points.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  15. Part 2: Clearance (CL)

    Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.

    Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.

  16. Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by OR.

    This applies to the subset of patients in the Basket Cohort who received prior therapy with a MET-targeting TKI. Documented OR (defined as PR or CR), assessed by RECIST v1.1 at any time during trial participation by Investigator assessment. Objective Response (OR) is presented. Documented OR was defined as partial response \[PR\] or complete response \[CR\]) as assessed by CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; CR = Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis).

    Time frame: 24 Months

  17. Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by DCR.

    This applies to the subset of patients in the Basket Cohort who received prior therapy with a MET-targeting TKI. Documented OR (defined as PR or CR), assessed by RECIST v1.1 at any time during trial participation by Investigator assessment. Disease control rate (DCR) is presented. The DCR was defined as the percentage of patients who had BOR of confirmed CR or confirmed PR or SD (including unconfirmed CR/PR, provided 6 weeks minimum criteria for SD duration was met). BOR = Best Overall Response. CR = Complete Response. PR = Partial Response. SD = Stable Disease.

    Time frame: 24 Months

08

Results

Posted Jun 22, 2022

Participant flow

Participant flow — Overall Study
MilestonePart 1: Dose-Escalation; Period 1: 6 mg/kgPart 1: Dose-Escalation; Period 2: 12mg/kgPart 1: Dose-Escalation; Period 3:18mg/kgPart 1: Dose-Escalation; Period 4: 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METEx14Del Cohort
Started333325812
Completed0000000
Not completed333325812
Withdrew: Withdrawal by subject0110100
Withdrew: Progressive disease22232278
Withdrew: Other reason (unknown)1000000
Withdrew: Protocol violation0000100
Withdrew: Death0000003
Withdrew: Physician decision0000101
Withdrew: Transferred to named patient program0000010

Outcome measures

PrimaryPart 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration

The primary objective of Part 1 was to assess the safety and tolerability of Sym015 on a Q2W schedule. This was assessed by evaluating the occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of Sym015 administration. Q2W = every second week.

Time frame:
Cycle 1, the initial 28-day period of Q2W dosing
Reported as:
Number · Number of DLTs
Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration
Number of DLTsPart 1: Dose-Escalation; Period 1, 6 mg/kgPart 1: Dose-Escalation; Period 2: 12mg/kgPart 1: Dose-Escalation; Period 3:18mg/kgPart 1: Dose-Escalation; Period 4: 24 mg/kg
Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration0000
PrimaryPart 2: Documented, Confirmed Objective Response (OR)

The primary objective of Part 2 was to evaluate the antitumor activity of Sym015 when administered at the Q2W RP2D to patients in the different cohorts. Documented OR was defined as partial response \[PR\] or complete response \[CR\]) as assessed by CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; CR = Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). Q2W = every second week. RP2D = recommended phase 2 dose.

Time frame:
24 months
Reported as:
Count of participants · Participants
Part 2: Documented, Confirmed Objective Response (OR)
ParticipantsPart 2: Basket CohortPart 2: Patients in NSCLC MET-Amplified CohortPart 2: Patients in NSCLC METEx14Del Cohort
Part 2: Documented, Confirmed Objective Response (OR)023
SecondaryPart 1: Determine a Q2W RP2D of Sym015.

Determination based on an evaluation of the patient data for DLTs from Part 1. Q2W = every second week. RP2D = recommended phase 2 dose.

Time frame:
12 Months
Reported as:
Number · mg/kg
Part 1: Determine a Q2W RP2D of Sym015.
mg/kgPart 1: Dose-Escalation (4 Arms Combined)
Part 1: Determine a Q2W RP2D of Sym015.NA
SecondaryImmunogenicity of Sym015: Part 1.

Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.

Time frame:
Cycle 1: Day (D) 1, Cycle 3, 5, 7: D1 (+-2), End of treatment: At or by D10, Follow-up: 1 month after last dose of study treatment (30+7D)
Reported as:
Count of participants · Participants
Immunogenicity of Sym015: Part 1.
Participants6 mg/kg12 mg/kg18 mg/kg24 mg/kg
Cycle 1 - day 1 — Not done0000
Cycle 1 - day 1 — Negative3333
Cycle 1 - day 1 — Patient withdrawn0000
Cycle 3 - day 1 — Not done0000
Cycle 3 - day 1 — Negative1020
Cycle 3 - day 1 — Patient withdrawn2313
End of treatment — Not done0001
End of treatment — Negative3212
End of treatment — Patient withdrawn0120
1-month follow-up — Not done0100
1-month follow-up — Negative2102
1-month follow-up — Patient withdrawn1131
SecondaryImmunogenicity of Sym015: Part 2.

Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.

Time frame:
Cycle 1: Day (D) 1, Cycle 2, 3, 5, 7: D1 (+-2), End of treatment: At or by D10, Follow-up: 1 month after last dose of study treatment (30+7D)
Reported as:
Count of participants · Participants
Immunogenicity of Sym015: Part 2.
ParticipantsPart 2: Basket CohortPart 2: Patients in NSCLC MET-Amplified CohortPart 2: Patients in NSCLC METEx14Del Cohort
Cycle 1 - day 1 — Not done000
Cycle 1 - day 1 — Negative25812
Cycle 1 - day 1 — Positive000
Cycle 1 - day 1 — Patient withdrawn000
Cycle 2 - day 1 — Not done100
Cycle 2 - day 1 — Negative21811
Cycle 2 - day 1 — Positive000
Cycle 2 - day 1 — Patient withdrawn301
Cycle 3 - day 1 — Not done110
Cycle 3 - day 1 — Negative878
Cycle 3 - day 1 — Positive000
Cycle 3 - day 1 — Patient withdrawn1604
Cycle 5 - day 1 — Not done001
Cycle 5 - day 1 — Negative665
Cycle 5 - day 1 — Positive000
Cycle 5 - day 1 — Patient withdrawn1926
Cycle 7 - day 1 — Not done010
Cycle 7 - day 1 — Negative225
Cycle 7 - day 1 — Positive000
Cycle 7 - day 1 — Patient withdrawn2357
End of treatment — Not done500
End of treatment — Negative1579
End of treatment — Positive100
End of treatment — Patient withdrawn413
1-month follow up — Not done011
1-month follow up — Negative1035
1-month follow up — Positive100
1-month follow up — Patient withdrawn1446
SecondaryPart 1: Area Under the Concentration-time Curve in a Dosing Interval (AUC) Following 1st Dose

Estimated using non-compartmental methods and actual time points following the first dose of Sym015.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · h*μg/mL
Part 1: Area Under the Concentration-time Curve in a Dosing Interval (AUC) Following 1st Dose
h*μg/mL6 mg/kg12 mg/kg18 mg/kg24 mg/kg
Part 1: Area Under the Concentration-time Curve in a Dosing Interval (AUC) Following 1st Dose17900 (17100 to 24500)35700 (31600 to 42900)82500 (75200 to 86200)76800 (55200 to 86400)
SecondaryPart 2: Area Under the Concentration-time Curve in a Dosing Interval (AUC)

Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · h*ug/mL
Part 2: Area Under the Concentration-time Curve in a Dosing Interval (AUC)
h*ug/mLPart 2 (Dose Expansion): Basket CohortPart 2 (Dose Expansion): Patients in NSCLC MET-Amplified CohortPart 2 (Dose Expansion): Patients in NSCLC METEx14Del Cohort
Part 2: Area Under the Concentration-time Curve in a Dosing Interval (AUC)34000 (17300 to 51800)37200 (22000 to 55000)38700 (11300 to 54000)
SecondaryPart 1: Cmax

Maximum serum concentration was derived from observed data.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · ug/mL
Part 1: Cmax
ug/mL6 mg/kg12 mg/kg18 mg/kg24 mg/kg
Part 1: Cmax146 (141 to 151)286 (275 to 323)563 (419 to 711)561 (379 to 726)
SecondaryPart 2: Cmax

Maximum serum concentration was derived from observed data following the first dose of Sym015 for the full basket cohort.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · ug/mL
Part 2: Cmax
ug/mLPart 2 (Dose-Expansion): Basket CohortPart 2 (Dose-Expansion): Patients in NSCLC MET-Amplified CohortPart 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort
Part 2: Cmax420 (310 to 700)520 (320 to 610)510 (330 to 1180)
SecondaryPart 1: Time to Reach Maximum Concentration (Tmax)

Time to reach maximum concentration (Tmax) was derived from observed data.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · hours
Part 1: Time to Reach Maximum Concentration (Tmax)
hours6 mg/kg12 mg/kg18 mg/kg24 mg/kg
Part 1: Time to Reach Maximum Concentration (Tmax)2.1 (2 to 5)1.1 (1 to 2)3.5 (3 to 4)3.0 (3 to 9)
SecondaryPart 2: Time to Reach Maximum Concentration (Tmax)

Time to reach maximum concentration (Tmax) was derived from observed data following the first dose of Sym015 for the full basket cohort.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · hours
Part 2: Time to Reach Maximum Concentration (Tmax)
hoursPart 2 (Dose-Expansion): Basket CohortPart 2 (Dose-Expansion): Patients in NSCLC MET-Amplified CohortPart 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort
Part 2: Time to Reach Maximum Concentration (Tmax)2.5 (1 to 44)3.7 (2 to 8)2.8 (2 to 7)
SecondaryPart 1: Trough Concentration (Ctrough)

Ctrough was derived from observed data.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · μg/mL
Part 1: Trough Concentration (Ctrough)
μg/mL6 mg/kg12 mg/kg18 mg/kg24 mg/kg
Part 1: Trough Concentration (Ctrough)23.1 (19.2 to 31.5)61.3 (56.1 to 65)130 (127 to 187)92.4 (91.3 to 151)
SecondaryPart 2: Trough Concentration (Ctrough)

Ctrough was derived from observed data following the first dose of Sym015 for the whole basket cohort.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · μg/mL
Part 2: Trough Concentration (Ctrough)
μg/mLPart 2 (Dose-Expansion): Basket CohortPart 2 (Dose-Expansion): Patients in NSCLC MET-Amplified CohortPart 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort
Part 2: Trough Concentration (Ctrough)84.1 (24 to 429)90.1 (51 to 183)101.7 (66 to 250)
SecondaryPart 1: Elimination Half-life (T½)

Estimated using non-compartmental methods and actual time points.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · hours
Part 1: Elimination Half-life (T½)
hours6 mg/kg12 mg/kg18 mg/kg24 mg/kg
Part 1: Elimination Half-life (T½)179 (116 to 179)137 (137 to 137)193 (193 to 193)170 (170 to 170)
SecondaryPart 2: Elimination Half-life (T½)

Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · hours
Part 2: Elimination Half-life (T½)
hoursPart 2 (Dose-Expansion): Basket CohortPart 2 (Dose-Expansion): Patients in NSCLC MET-Amplified CohortPart 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort
Part 2: Elimination Half-life (T½)150 (87 to 217)191 (103 to 208)171 (116 to 204)
SecondaryPart 1: Clearance (CL)

Estimated using non-compartmental methods and actual time points.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · mL/h
Part 1: Clearance (CL)
mL/h6 mg/kg12 mg/kg18 mg/kg24 mg/kg
Part 1: Clearance (CL)0.3 (0.3 to 0.3)0.2 (0.2 to 0.2)——
SecondaryPart 2: Clearance (CL)

Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.

Time frame:
From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Reported as:
Median · mL/h/kg
Part 2: Clearance (CL)
mL/h/kgPart 2 (Dose-Expansion): Basket CohortPart 2 (Dose-Expansion): Patients in NSCLC MET-Amplified CohortPart 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort
Part 2: Clearance (CL)0.4 (0.2 to 0.5)0.2 (0.2 to 0.2)0.2 (0.2 to 0.2)
SecondaryPart 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by OR.

This applies to the subset of patients in the Basket Cohort who received prior therapy with a MET-targeting TKI. Documented OR (defined as PR or CR), assessed by RECIST v1.1 at any time during trial participation by Investigator assessment. Objective Response (OR) is presented. Documented OR was defined as partial response \[PR\] or complete response \[CR\]) as assessed by CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; CR = Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis).

Time frame:
24 Months
Reported as:
Count of participants · Participants
Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by OR.
ParticipantsPatients With Prior MET-targeting TKI Therapy (Basket Cohort)Patients Without Prior MET-targeting TKI Therapy (Basket Cohort)
Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by OR.00
SecondaryPart 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by DCR.

This applies to the subset of patients in the Basket Cohort who received prior therapy with a MET-targeting TKI. Documented OR (defined as PR or CR), assessed by RECIST v1.1 at any time during trial participation by Investigator assessment. Disease control rate (DCR) is presented. The DCR was defined as the percentage of patients who had BOR of confirmed CR or confirmed PR or SD (including unconfirmed CR/PR, provided 6 weeks minimum criteria for SD duration was met). BOR = Best Overall Response. CR = Complete Response. PR = Partial Response. SD = Stable Disease.

Time frame:
24 Months
Reported as:
Count of participants · Participants
Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by DCR.
ParticipantsPatients With Prior MET-targeting TKI Therapy (Basket Cohort)Patients Without Prior MET-targeting TKI Therapy (Basket Cohort)
Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by DCR.28

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Dose-Escalation; Period 1: 6 mg/kg0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Part 1: Dose-Escalation; Period 2: 12mg/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part 1: Dose-Escalation; Period 3:18mg/kg0/3 (0%)0/3 (0%)3/3 (100%)
Part 1: Dose-Escalation; Period 4: 24 mg/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part 2: Dose-Expansion, Basket Cohort0/25 (0%)8/25 (32%)23/25 (92%)
Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort0/8 (0%)4/8 (50%)8/8 (100%)
Part 2: Dose-Expansion, NSCLC METEx14Del Cohort3/12 (25%)6/12 (50%)12/12 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPart 1: Dose-Escalation; Period 1: 6 mg/kgPart 1: Dose-Escalation; Period 2: 12mg/kgPart 1: Dose-Escalation; Period 3:18mg/kgPart 1: Dose-Escalation; Period 4: 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METEx14Del Cohort
Pelvic abscessInfections and infestations1/30/30/30/30/250/80/12
Intra-abdominal fluid collectionGastrointestinal disorders0/30/30/31/30/250/80/12
NauseaGastrointestinal disorders0/31/30/30/30/250/80/12
BacteraemiaInfections and infestations0/30/30/31/30/250/80/12
PneumoniaInfections and infestations0/30/30/30/30/251/81/12
InfectionInfections and infestations0/30/30/30/30/251/80/12
Septic shockInfections and infestations0/30/30/30/30/251/80/12
Edema peripheralGeneral disorders0/30/30/30/30/251/80/12
HepatitisHepatobiliary disorders0/30/30/30/30/251/80/12
Peripheral ischemiaVascular disorders0/30/30/30/30/251/80/12
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPart 1: Dose-Escalation; Period 1: 6 mg/kgPart 1: Dose-Escalation; Period 2: 12mg/kgPart 1: Dose-Escalation; Period 3:18mg/kgPart 1: Dose-Escalation; Period 4: 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METEx14Del Cohort
HypokalemiaMetabolism and nutrition disorders2/30/31/30/32/250/80/12
Ear painEar and labyrinth disorders0/32/30/31/30/250/80/12
Infusion related reactionInjury, poisoning and procedural complications0/30/32/30/30/250/80/12
Edema peripheralGeneral disorders1/31/30/30/31/253/87/12
CoughRespiratory, thoracic and mediastinal disorders0/31/30/30/32/251/85/12
Aspartate aminotransferase increasedInvestigations0/30/30/30/31/253/81/12
HeadacheNervous system disorders0/30/31/30/30/253/80/12
Back painMusculoskeletal and connective tissue disorders0/30/30/30/33/253/80/12
NauseaGastrointestinal disorders1/30/30/30/36/252/82/12
ConstipationGastrointestinal disorders0/31/30/31/35/252/82/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Dose-Escalation, 6 mg/kgPart 1: Dose-Escalation, 12 mg/kgPart 1: Dose-Escalation 18 mg/kgPart 1: Dose-Escalation 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METex14del CohortTotal
Mean55.7 ± 14.5762.0 ± 11.7955.3 ± 11.2467.3 ± 7.2356.6 ± 11.8765.6 ± 8.9168.5 ± 9.8261.1 ± 11.73
Age, Customized
Age, Customized(Participants)Part 1: Dose-Escalation, 6 mg/kgPart 1: Dose-Escalation, 12 mg/kgPart 1: Dose-Escalation 18 mg/kgPart 1: Dose-Escalation 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METex14del CohortTotal
18-65 years2121202634
65 to <75 years121245015
75 to <85 years00001168
85 years or older00000000
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Dose-Escalation, 6 mg/kgPart 1: Dose-Escalation, 12 mg/kgPart 1: Dose-Escalation 18 mg/kgPart 1: Dose-Escalation 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METex14del CohortTotal
Female122275625
Male2111183632
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Dose-Escalation, 6 mg/kgPart 1: Dose-Escalation, 12 mg/kgPart 1: Dose-Escalation 18 mg/kgPart 1: Dose-Escalation 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METex14del CohortTotal
Hispanic or Latino00021014
Not Hispanic or Latino33312481153
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Dose-Escalation, 6 mg/kgPart 1: Dose-Escalation, 12 mg/kgPart 1: Dose-Escalation 18 mg/kgPart 1: Dose-Escalation 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METex14del CohortTotal
American Indian or Alaska Native00000000
Asian0000142117
Native Hawaiian or Other Pacific Islander00000000
Black or African American10001002
White2332861135
More than one race00001001
Unknown or Not Reported00011002
Region of Enrollment
Region of Enrollment(participants)Part 1: Dose-Escalation, 6 mg/kgPart 1: Dose-Escalation, 12 mg/kgPart 1: Dose-Escalation 18 mg/kgPart 1: Dose-Escalation 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METex14del CohortTotal
South Korea0000122014
United States333363829
Taiwan00001001
Denmark00000112
Spain000062311
Body weight
Body weight(kg)Part 1: Dose-Escalation, 6 mg/kgPart 1: Dose-Escalation, 12 mg/kgPart 1: Dose-Escalation 18 mg/kgPart 1: Dose-Escalation 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METex14del CohortTotal
Mean82.2 ± 17.8662.5 ± 12.0389.0 ± 18.2969.7 ± 8.0567.1 ± 10.7360.3 ± 11.5872.1 ± 15.5469.1 ± 13.86
Body mass index (BMI)
Body mass index (BMI)(kg per square meter)Part 1: Dose-Escalation, 6 mg/kgPart 1: Dose-Escalation, 12 mg/kgPart 1: Dose-Escalation 18 mg/kgPart 1: Dose-Escalation 24 mg/kgPart 2: Dose-Expansion, Basket CohortPart 2: Dose-Expansion, NSCLC MET-Amplified CohortPart 2: Dose-Expansion, NSCLC METex14del CohortTotal
Mean28.10 ± 1.13223.65 ± 3.97829.84 ± 7.45225.89 ± 5.36323.58 ± 3.77622.15 ± 4.59025.19 ± 4.08124.44 ± 4.405

8 further baseline measures are reported on the registry.

09

Study locations

27 sites
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Indiana University Health Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute/D -1251
    Boston, Massachusetts 02215, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • South Texas Accelerated Research Therapeutics, LLC
    San Antonio, Texas 78229, United States
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • CHA Bundang Medical Center, CHA University
    Seongnam-si, Gyeonggi-do 13496, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Gangnam Severance Hospital, Yonsei University Health System
    Seoul, 06273, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 08308, Korea, Republic of
  • Hospital Universitario Quiron Dexeus
    Barcelona, Barcelona/Cataluna 08028, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, Barcelona/Cataluna 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Barcelona/Cataluna 08036, Spain
  • Centro Oncologico MD Anderson
    Madrid, 28033, Spain
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
  • Taipei Medical University Hospital
    Taipei, 11031, Taiwan
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan
10

References and documents

Publications

  • Grandal MM, Havrylov S, Poulsen TT, Koefoed K, Dahlman A, Galler GR, Conrotto P, Collins S, Eriksen KW, Kaufman D, Woude GFV, Jacobsen HJ, Horak ID, Kragh M, Lantto J, Bouquin T, Park M, Pedersen MW. Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms. Mol Cancer Ther. 2017 Dec;16(12):2780-2791. doi: 10.1158/1535-7163.MCT-17-0374. Epub 2017 Aug 11. PubMed 28802255 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Dec 2020, 57 months.

Results were first posted in Jun 2022, 1 year 6 months after primary completion.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 57 months is close to that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2016
First posted
Jan 7, 2016
StartActual
Mar 2016
Primary completionActual
Dec 2020
CompletionActual
Dec 2020
Results first posted
Jun 22, 2022
Last update
Jun 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02648724
Lead sponsor
Symphogen A/S
Responsible party
Sponsor
First posted
Jan 7, 2016
Start date
Mar 2016
Primary completion
Dec 2020
Completion
Dec 2020
Results posted
Jun 22, 2022
Last update
Jun 22, 2022

Study contacts

Amita Patnaik, MD, FRCP(C)
principal investigator · South Texas Accelerated Research Therapeutics, LLC
David Ross Camidge, MD, PhD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion